These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

456 related articles for article (PubMed ID: 8421084)

  • 1. Effect of growth hormone (GH)-releasing hormone (GHRH), atropine, pyridostigmine, or hypoglycemia on GHRP-6-induced GH secretion in man.
    Peñalva A; Carballo A; Pombo M; Casanueva FF; Dieguez C
    J Clin Endocrinol Metab; 1993 Jan; 76(1):168-71. PubMed ID: 8421084
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Massive growth hormone (GH) discharge in obese subjects after the combined administration of GH-releasing hormone and GHRP-6: evidence for a marked somatotroph secretory capability in obesity.
    Cordido F; Peñalva A; Dieguez C; Casanueva FF
    J Clin Endocrinol Metab; 1993 Apr; 76(4):819-23. PubMed ID: 8473389
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acipimox-mediated plasma free fatty acid depression per se stimulates growth hormone (GH) secretion in normal subjects and potentiates the response to other GH-releasing stimuli.
    Peino R; Cordido F; Peñalva A; Alvarez CV; Dieguez C; Casanueva FF
    J Clin Endocrinol Metab; 1996 Mar; 81(3):909-13. PubMed ID: 8772549
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of endogenous cholinergic tone and alpha-adrenergic pathways on growth hormone responses to His-D-Trp-Ala-Trp-D-Phe-Lys-NH2 in the dog.
    Muruais J; Peñalva A; Dieguez C; Casanueva FF
    J Endocrinol; 1993 Aug; 138(2):211-8. PubMed ID: 8228729
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of combined administration of growth hormone (GH)-releasing hormone, GH-releasing peptide-6, and pyridostigmine in normal and obese subjects.
    Cordido F; Peñalva A; Peino R; Casanueva FF; Dieguez C
    Metabolism; 1995 Jun; 44(6):745-8. PubMed ID: 7783658
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low hexarelin dose and pyridostigmine have additive effect and potentiate to the same extent the GHRH-induced GH response in man.
    Arvat E; Di Vito L; Ramunni J; Gianotti L; Giordano R; Deghenghi R; Camanni F; Ghigo E
    Clin Endocrinol (Oxf); 1997 Oct; 47(4):495-500. PubMed ID: 9404449
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evidence that alpha 2-adrenergic pathways play a major role in growth hormone (GH) neuroregulation: alpha 2-adrenergic agonism counteracts the inhibitory effect of muscarinic cholinergic receptor blockade on the GH response to GH-releasing hormone, while alpha 2-adrenergic blockade diminishes the potentiating effect of increased cholinergic tone on such stimulation in normal men.
    Devesa J; Diaz MJ; Tresguerres JA; Arce V; Lima L
    J Clin Endocrinol Metab; 1991 Aug; 73(2):251-6. PubMed ID: 1677361
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impaired growth hormone secretion in obese subjects is partially reversed by acipimox-mediated plasma free fatty acid depression.
    Cordido F; Peino R; Peñalva A; Alvarez CV; Casanueva FF; Dieguez C
    J Clin Endocrinol Metab; 1996 Mar; 81(3):914-8. PubMed ID: 8772550
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Growth hormone (GH) response to GH-releasing peptide-6 in patients with insulin-dependent diabetes mellitus.
    Villas-Boas Weffort RF; Ramos-Dias JC; Chipoch C; Lengyel AM
    Metabolism; 1997 Jun; 46(6):706-10. PubMed ID: 9186309
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of growth hormone-releasing peptide 1-6 on GH secretion-stimulated by GHRH and pyridostigmine in lambs.
    Rico M; Rueda V; Lorenzo MT; Núñez A; De la Cruz LF
    J Physiol Biochem; 1998 Jun; 54(2):67-76. PubMed ID: 9858126
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acute growth hormone (GH) response to GH-releasing hexapeptide in humans is independent of endogenous GH-releasing hormone.
    Robinson BM; Friberg RD; Bowers CY; Barkan AL
    J Clin Endocrinol Metab; 1992 Oct; 75(4):1121-4. PubMed ID: 1400881
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cholinergic receptor activation by pyridostigmine restores growth hormone (GH) responsiveness to GH-releasing hormone administration in obese subjects: evidence for hypothalamic somatostatinergic participation in the blunted GH release of obesity.
    Cordido F; Casanueva FF; Dieguez C
    J Clin Endocrinol Metab; 1989 Feb; 68(2):290-3. PubMed ID: 2493023
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of enhancement of endogenous cholinergic tone with pyridostigmine on the dose-response relationships of growth hormone (GH)-releasing hormone-induced GH secretion in normal subjects.
    Peñalva A; Muruais C; Casanueva FF; Dieguez C
    J Clin Endocrinol Metab; 1990 Feb; 70(2):324-7. PubMed ID: 2105328
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Blocked growth hormone-releasing peptide (GHRP-6)-induced GH secretion and absence of the synergic action of GHRP-6 plus GH-releasing hormone in patients with hypothalamopituitary disconnection: evidence that GHRP-6 main action is exerted at the hypothalamic level.
    Popovic V; Damjanovic S; Micic D; Djurovic M; Dieguez C; Casanueva FF
    J Clin Endocrinol Metab; 1995 Mar; 80(3):942-7. PubMed ID: 7883854
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Growth hormone secretion after the administration of GHRP-6 or GHRH combined with GHRP-6 does not decline in late adulthood.
    Micic D; Popovic V; Kendereski A; Macut D; Casanueva FF; Dieguez C
    Clin Endocrinol (Oxf); 1995 Feb; 42(2):191-4. PubMed ID: 7734029
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regulation of His-dTrp-Ala-Trp-dPhe-Lys-NH2 (GHRP-6)-induced GH secretion in the rat.
    Mallo F; Alvarez CV; Benitez L; Burguera B; Coya R; Casanueva FF; Dieguez C
    Neuroendocrinology; 1993; 57(2):247-56. PubMed ID: 8510800
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evidence against depletion of the growth hormone (GH)-releasable pool in human primary hypothyroidism: studies with GH-releasing hormone, pyridostigmine, and arginine.
    Valcavi R; Valente F; Dieguez C; Zini M; Procopio M; Portioli I; Ghigo E
    J Clin Endocrinol Metab; 1993 Sep; 77(3):616-20. PubMed ID: 8103770
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanisms underlying the negative growth hormone (GH) autofeedback on the GH-releasing effect of hexarelin in man.
    Arvat E; Di Vito L; Gianotti L; Ramunni J; Boghen MF; Deghenghi R; Camanni F; Ghigo E
    Metabolism; 1997 Jan; 46(1):83-8. PubMed ID: 9005975
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Growth hormone (GH)-releasing peptide stimulates GH release in normal men and acts synergistically with GH-releasing hormone.
    Bowers CY; Reynolds GA; Durham D; Barrera CM; Pezzoli SS; Thorner MO
    J Clin Endocrinol Metab; 1990 Apr; 70(4):975-82. PubMed ID: 2108187
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cholinergic control of growth hormone (GH) responses to GH-releasing hormone in insulin dependent diabetics: evidence for attenuated hypothalamic somatostatinergic tone and decreased GH autofeedback.
    Ismail IS; Scanlon MF; Peters JR
    Clin Endocrinol (Oxf); 1993 Feb; 38(2):149-57. PubMed ID: 8094648
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.